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Phorb~l.e~ter~ hawe been ~thown tomodulate he//.adr©ner|i¢.~timulated adenylyl c)'cla~ in n number el'cell ine~. Here, us[nit ~ila directed muta. 
genesis, we invesligate the role of the #~.adrencrgic receptor phosphorylation by protein kin~se C in thi,~ regulatory process Mulation of the serinc. 
281, -~$2, -144 ,rid -345 el" the//.,.adren~rili¢ ¢c  ptor prevented the phorhol.ester-induced phosphorylation of Ihe receptor. This nBll~lIOn also 
;tholi*hed the phorbol.o~ter.induccd de rease in high.dignity ~llonist binding and potency of th~/t.,-adren~rlli¢ r©ceptor, We sUlllleSt thai protein 
kina~e C mediated pho~phorylation of the receptor promote,~ it~ functional uncoupling, 
#.,-Adr~nerill¢ r~ept~r; Pho~pllcryiation: Protein klna~ C; Adcnylyl cyela~e: Desensitization: Phorbol.ester; Reeeplor uncoupling 
1. INTRODUCTION 
Cross-regulation among transmembrane signalling 
systems has recently attracted considerable attention 
(for a review see [1]), In particular, tnodulation of the 
adenylyl cyclase reactivity by the stimulation of recep- 
tors coupled to the phospho-inositides (PI) turnover 
pathway has been reported [2,3]. The observation that 
the protein kinase C (PKC) activators, phorbol-esters, 
mimick these modulating effects in many cell lines 
[4-15] has led to the proposal e ra  role for PKC in this 
inter.system regulatory mechanism. However, the ef- 
fects of PKC-mediated phosphorylation the adenylyl 
cyclase reactivity appear to be rather complex, and both 
desensitization [10-15] and supersensitization [4-9] 
have been reportecl following phorbol-ester t eatments, 
In many mammalian cell lines, hormone-, fluoride- 
and GTP.stimulated adenylyl cyclase activities have 
been shown to be enhanced by phorbol-ester t eatment 
[4-9]. Phosphorylation by PKC of the inhibitory GTP- 
binding protein (G~) [16,17] and of the adenylyl cyclase 
catalytic unit itself [18,19] have been proposed to con- 
tribute to this sensitization effect of the phorbol-esters. 
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In sharp contrast, phorbol-ester treatment has been 
shown to induce a desensitization f the ~-adrenergic- 
stimulated adenylyl cyclase in avian erythrocytes 
[14,15], Desensitization was accompanied by an in- 
creased phosphorylation of the ~a-adrenergic receptor 
(#2AR), It was susgested that PKC-mediated 
phosphorylation f the receptor could contribute to this 
desensitization, The mammalian B2AR receptor has 
been shown to be an in vitro substrata for PKC [20], 
and potential PKC phosphorylation sites are apparent 
m its primary structure [21,22]. Thus, questions arise 
concerning the role of the PKC-mediated phosphoryla, 
tion of  the ~2AR in mammalian cellular systems. To 
evaluate the effects of the phosphorylation i such a 
system, a #2AR lacking potential PKC phosphorylation 
sites was constructed by site directed mutagenesis and 
expressed in Chinese hamster fibroblasts (CHW-I 102), 
The influence of 4~-phorbol 12t3-myristate 13c~-acetate 
(PMA) treatment on the phosphorylation level of the 
receptor and on the ~.q-adrenergic-stimulated denylyl 
cyclase activity were then evaluated in cells expressing 
either the wild type (WT) or the mutant (PKC-~zAR). 
2, MATERIALS AND METHODS 
2,1. Materials 
Carrier-free 32Pi, [12sl]CYP, [~-~P]ATP and [~H]cAMP were ob- 
tained from New Ensland Nuclear. Isoproterenol, ATP, GTP, 
cAMP, phosphoenol pyruvate, myokinase were purchased from 
Sigma, Pyruvate kinase and isobutylmethylxanthine were from 
Calbiochem, Digitonin was purchased from Gallard.Schlessinger, 
Geneticin (G418)0 DMEM, fetal calf serum, penicillin, streptomycin, 
amphotericin B and trypsin were purchased from Oibco. The site 
directed mutagenesis k t was obtained from Amersham. The expres- 
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)ion v~or  pBCl21tl w~t lecherously prmld~d by Dr B, t:ullen (Duke 
Urd~r~,hy). Alprenolol was ~ Ilen,~rou,, lilt( from IHa~d¢ phar- 
maceutical (.~;weden), 
2,2, .~it¢ diverted mut#lt¢~w~i~ #ml ¢¢11 ll'(#~.[¢¢ll~n 
A mutant Iluman ~|AR w~t eoo~lrtlgted wll~r¢ ~¢ri~¢-261, s s 
• .'144, and -~45 have ~¢n rcpl~teed by al~niae~. The/~'¢oRl.tfindlll 
frajmenl of pSPNAR [23} contain hi| the d~AR ¢~tltn| ~¢quen<e wa~ 
cloned illto the E¢oRl-t l iadl l l  sites of pTZISR (Pharma¢la), $ialile 
~tranded DNA was lletwraled u~,in$ VCS.MIJ h~:lper pllat~e 
($tr~tallen¢) and ~¢rved a~ a template for oll$onu¢leotkle directed 
mutallene~is (Amersham kit}, For eu,:aryo|k: expre~i,on, tl~e E¢o, 
RI-Hh)dl l l  frallment of the mutant altd wild type eon~trtlgtS ware 
xubdoned itt the Hi~tdlll.Baml )h~ of pflCI21:~l [24] and 
¢otransfe~:ted with PSV2-ne~ [2~) into Chin¢se Itatn~ter ibrobl~.~t~ 
1101 (CHW) by ,:al¢lum pl~o)phale pre~:ipit~tlon [26). POsilive clones 
,~cle~:ted for their re~i~tan¢¢ toneomycin (C14l~; i~0 p~/mi) were then 
s~reened for ~:AR expre~.~ion I a radio.lisand bindind a~ay, tl~inll 
400 pM [~:~IICYP a~ the radlolilland and l0 I=M alprenolol to define 
spe,:iric bindinll, 
2,:i, Cell euhure 
The transfeeted CHW col,., were grown as monolayers ill "~ cm = 
flasks ~:ontalning DMEM supplemented whh 10% fetal ~alr serum, 
penicillin (100 U/roll, streptomycin (100),g/roll, amphotericin B 
(0.25 pg/ml), and 8h||amine (I mMJ  in an almosphere of 9~% ~ir ~nd 
5% COz  at 37'C, 
2,4 Membrane preparolim) 
Cells were im:ubated for various p<riods of time at 3"/'C wid~ 
DMEM supplemented as above and ~¥ith or without PMA at the 
specified concentrations1 Cells were washed with PBS and lysed witit 
a poiytron homogenizer (2 bursts of S s) in l0 ml of ice.cold ~ mM 
Tris-HCI (pH ?,4), 2 mM EDTA, The tysate was centrifused at 4~ O00 
x g for 20 rain and waslted twice in the same buffer, Tire pelleted 
melnbranes were resuspended in 0,6 ml of a buffer containing 75 mM 
Tris-HCI (pH 7,4), 12,5 mM MgCh and 2 mM EDTA and used ira. 
mediately, Protein content was determined according to tl~e method 
of Bradford [27J (Biorad), 
2,5, Adenylyl cyclas¢ assay and radio.ligand binding assay 
Adenylyl cyclase activity was measured by the method of Satomon 
etal, [28] as previously described [29] using - 20 #8 of membrane pro- 
tein in a total volume of 0.05 ml, The incubation mixture included 
0,12 mM ATP, I pCi [uJzP]ATP, 0,1 mM cAMP 0,053 mM GTP, 
2,8 mM phosphoenolpyruva/e, 0,2 U of pyrt|vate kinase, I U of 
myokinase, 30 mM Tris-HCI (pH "7,4), 5 mM MgCl: and 0,8 mM 
EDTA, Enzyme activity was determined in triplicate in the absence 
(i.e, basal activity) or in the presence of activators (isoproterenol 
0-100 ~.M, forskolin 0-100 #M), Radlo-llgand binding assays were 
conducted essentially as described [29] using - 10 ~¢g of membrane 
protein in a total volume of 0,5 ml. For saturation experiments, 
duplicate ¢t,,,~y t~ contained ~=4Oa pM I"='IWYi ) tn the prwene= 
arld ~h,~r~,~ of  I0 ~,M alpr~nolol, For ,/ompeth on ¢,~pcrimentt 
duplicate a~'  tuh¢~ coat,tiled -~O pM lw:~IJCYP and 0-100 mM 
hopn)terenol. The bindinll r¢~<tioflt w,~re terminated by rapid fll~rA, 
Zion on Whatman (.W/(.' illaV~ 131~r tilters, I)alct from tampa(ilion 
and s.tur~tlon e,~pertment,= wer~ an~ly~ed by non,line~r le~t.tqu~re~ 
relltevdoo w~lnp the ¢oml~Jter prosram [.I¢3AND [}0l, 
2,6, If'hole ¢'¢fl phosphor.elation 
C~lh wer~,detaehed, wzttl~¢l twi<e with phe'~phate.free DMEM aitd 
prein*;ubaled in tht'~ medium for 60 rain at )?'C. Carrier.free ~;P, ~0,$ 
mCI/ml) wa~ then added to tlte medium and the twill, Im:ul~ted rot. ~fl 
additional 60 mtn at ~,'/'~G, At the end tar thit eq~)illbr~tlon pcrtod, 
PMA tip pM) or ~he vehNle was attded 7o th.~ ¢¢1h and Incubated =tt 
)7"C rot I ~, rain, The edh, ~'err then ly)ed by ~onleatlon In lee<old 
burrer cornaininil 20 mM TrI~-HCI (pH ?.4), .~ mM F=DTA, [0 mM 
Na:FIPO,h leul~Ptin ~ pl~/ml, soybean trypdn Sahib tar .~ ~qllml ~ld 
ben~amld ne l0 #~/n'd, The ntembranes were then centriful~ed at 
40 000 x ,it and wathed twice ia the same burrer, The washed mere. 
brahe prelmration~ were sotnbl I~ed in 10OmM NaCI, IO mM Trlr,. 
HCI (pH "/.4). ~ mM EDTA, 2% di$itonifl at 4"C ftar 2 h anti tile 
J~:AR purified by alprenoloI.Sepharo~e affinity cl~rontatollraph:., as 
described elsewhere [:ell, 
2,?. SD.S'.pol.vacry/amit/e Xel e/e¢/rophotesi.v 
Gel de,:trophore~ls was perforated a~:~:ordin= to the method of 
Laemmli [32) wlH1 10-12% slab gels, The amount or receptor loaded 
on the ~el was monitored by* radio-lignnd binding u~ing 400 pM 
(=:sl]CYP and l0  mM alpr©nolol to define the specific binding, The 
binding rem:tion~ were terminated by passing the samples tltrotlSh 
Sephadex G.25 columns at 4"C, After electrophoresis, the 8¢1s were 
dried and atnoradiographed at -90"C usin8 Kodak XAR-$ I'ilm. 
3. RESULTS AND DISCUSSION 
A mutant  flyAR lacking potential  phosphorylat ion 
sites for PKC was constructed by site direct mutagenesis 
of  the human flyAR eDNA,  Serine and threonine 
residues f lanked on both sides by basic amino acids 
have been proposed as potent ia l  PKC phosphorylat ion 
sites in many pep(ides and proteins [33]. The 
serines-261, -262, -344 and -345 of the human flzAR 
fulfill this cr i ter ion and were replaced by alanine 
residues (PKC- f lyAR)  (Scheme 1), Both wild type 
(WT) and  mutant  receptor cDNA constructs were 
t ransfected in CHW. I  102 cells (see section 2), Cell l ines 
expressing comparab le  levels of  receptors were used for 
the study (WTflyAR: 1.2:l=0,1 pmol /mg protein, vs 
PKC - (~yAR: 1.4 +_ 0,2 pmol /mg protein),  
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Table I 
Adenylyl cyclase activity (pmol/min/mg) 
C¢II line Basal [soproterenol-stlmulated Forskolin.stimulated 
Ctrl PMA Ctrl PMA Ctrl PMA 
Wt~yAR 20±3 48+-13 34__.4 101+-9 94+- 14 179=:57 
(n = 7) 
PKC" ~yAR 16±4 34±7 28+_5 80+11 98.+18 166±28 
(n = 4) 
Cells expressing either WTflyAR or PKC-32AR were pretreated (PMA) or not (Ctrl) with l0 #M PMA 
for 30 rain, The basal, isoproteronol-stimulated (I00 ~M) and forskolin.stimulatcd (I00 ~.M) adenylyl 
cyclase activities were measured as described in section 2, Values represent the mean ",- SEM. 
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gil il i 
~'Og~*'.. _ . . . . . . . . . . . . . . . .  
Sc)ici11¢ I, S~;h¢irl|ilh; reprCS¢l'daliOll or II~¢ poslnl{tl¢{l Itl~nsfll~fflbral~e 
or~Itlt~,¢ltliQIt of the humnn IL, AR, The arrows tndh:ale Ih¢ setin¢ 
residues 261,262,344 and 34,S which were mutaled Io ¢tlanincs by IlW 
¢lir¢~;Ic¢l I ttllallelleSls Ira llenerale PKC "d-,~,g, 
The mutation did not affect the affinity of the recep- 
tor for the antagonist [==~IICYP (data not shown) nor 
did it significantly change the ability of the receptor to 
mediate isoproterenol-stimulation of the adenylyl 
cyclase (Table I). However, the mutation completely 
abolished the PMA-induccd phosphorylation of the 
receptor, Indeed as has been reported in other cell types 
[14,15], an incubation of 15 rain with 10 ~M PMA in- 
duced a significant increase in the phosphorylation level 
of the WT~=AR expressed in CHW-1102 cells whereas 
the same treatment did not alter the phosphorylation 
level of PKC" ~2AR (Fig. 1). These results uggest that 
one or more of the mutated serines ~s the major PKC 
pl~osphorylation site(s) of the B, AR. 
In ¢ell~ ¢~pressinl! WT#=AR PMA induces a time. 
and dose. dependent incre~lse in basal, isoproterenol. 
stimulated and forskolin.sdmulated adenylyl eyclas¢ 
activities, As Illustrated tn Fill, 2, the maximal effects of" 
the PMA treatment on the adenylyl cycl~s¢ activities 
were observed follmvin8 a 30 rain incubation with 10 
#M PMA, and therefore these conditions were used i~ 
subsequent e,xperiments, Table I summarizes the effects 
of this PMA treatment on the basal and stimulated 
adenylyt cyclas¢ activities in cells expr~ssinll WT#=AR 
and PKC ~ B=AR. In botl~ cell lines, PMA induces an in. 
crease in the basal activity as well as in the maximum ac- 
tivity when stimulat~d by isoproterenol (100/~M) and 
forskolin (100 t4M). The sensitizing effect of the PMA 
was virtually identi~:al in the two cell lines. However, 
wl~en the effect of PMA was assessed on full 
dose-response curves in cells expressing the WT,~AR, 
the PMA treatment induced a S-fold increase in the 
ECso of adenylyl cyclase stimulation by isoproterenol 
(Ctrl: 60.-8 nM vs PMA treated 300.-30 riM, it=S). 
This PMA-induced decrease in potency was abolished 
by mutation of the ¢ serines. Indeed, the ECso of t~e 
adenylyl cyclase stimulation by isoproterenol was not 
affected by the PMA treatment in cells expressing 
PKC-~=AR (Ctrh 110.-20 nM vs PMA treated: 
lO0 ± l0 nM; t~= 5), This effect on the potency appears 
receptor specific since PMA Ireatment did not affect 
the ECaa of adenylyl cyclase stimulation by forskoRn 
(data not shown). 
The total amount of ~=AR, as assessed by [~=Sl]cYP 
binding was not affected by the PMA treatment in 
either cell line (WTflAR: Ctrl; !.2:1:0.1 pmol/mg vs 
PMA; 1.34-0.2 pmol/mg PKC'IBzAR: Ctrl; 1.4.-0.2 
pmollmg vs PMA; 1.4-+0.2 pmollmg). However, the 
4-  
c- 





[ ]  Control 
r'q PMA 
WTI32AR PKC" 132AR 
T 
Control PMA Control PIMA 
B2AR 
WTB2AR PKC "I32AR 
Fig. l, Phorb01-ester-induced phosphorylation f WT and PKC "(~AR. The phosphorylation levels werequantitated by densltometri¢ analysis of 
SDS-PAGE autoradiographs. The level of PMA induced phosphorylation f/%AR is expressed as a ratio of  the basal evel and represents he mean 
:t: SEM of 4 separate xperiments. (inset) A representative autoradiograph of a SDS-PAGE of the purified receptor is shown. 
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Fig, 2 Effects of PMA treatment on tl~a basal, isoproterenol.stimulated and forskolin-stimulat¢cl adenylyl ty¢la~¢ activity in cells expressing 
WT~zAR, Left panel: cells were incubated for 30 rain with increasint¢ concentrations of PMA. Ri@.t panel; telh were incubated witl~ lO/=M PMA 
for various periods of time, The adenylyl cyclase activities were determined in membranes derived from these cells as described in sectio,~ 2, The 






Cont ro t  
[ " - '1  PMA 
WT,6'= AR PKC-~z AR 
Fig, 3, Effects of PMA treatment or the proportion of ~3=AR in the 
high affinity state for the agonist isoproteronol, The proportions were 
deterdzi~efl fto~ di~,plac~ment turves of [12Jl]CYP binding by 
isoproterenoI {10- ~o M to I0" 4 M) as described insection 2. The data 
are expressed as °70 of the total receptor number and represent the 
mean -,- SEM of three separate xperiments. The high and low af- 
finities are as follows: WT: K.: 1,5:t:0,7 nM, KL: 248±39 nM; 
PKC - :A'H; 6,2 :: 1.5 nM, KL 274 ± tO nM. 
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agonist binding properties of WT(3zAR were 
significantly affected by the tumor promoter. 
Isoproterenol competit ion of [12SI]CYP binding reveal- 
ed that WT/32AR and PKC-/32AR exhibit the 
characteristic two-affinity state binding for agonist 
(data not shown). Using the computer program 
L IGAND [30], 31:1:4% and 21 :t:4% of the total recep- 
tor contingent in cells expressing WT/32AR and 
PKC-~2AR respectively, are found to be in the 
guanine-nuclcotide-sensitive high-affinity state for 
isoproterenol (Fig. 3). When WT/32AR expressing Cells 
were treated with I0 ,=M PMA for 30 rain the propor- 
tion of (32AR in high aff inity was dramatically reduced 
(Fig. 3). In contrast, the same treatment in cells express- 
ing PKC "/32AR did not reduce the proport ion of  recep- 
tor in the high affinity state, It is generally accepted that 
the proport ion of receptor in the guanine-nucleotide- 
sensitive high-affinity state for its agonist represents the 
ability of  the receptor to couple to (3s [34]. These results 
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therefore suilsest that PKC-mediated phosphoryla¢ion 
of  the #=AR reduces its capacity to couple to G.. Un- 
coupling of a ~liniflcant proportion or the receptor, 
which is not observed with PKC ~ d:AR,  could be 
responsible for the PMA-induced decrease in 
l ie proterenol potency observed in WT/~=AR expressing 
cells, Similarly. it has recently been shown that cAMP.  
promoted phosphorylation of  the ~:AR also leads to .  
decrease in the potency with no chanl~ein the efficacy or 
adenylyl cyclase stimulatton by ~.adrenergic agonists 
[3S-37], 
The results presented here also sulilest that the PMA- 
induced increase in the efficacy of  adenylyl cyclase 
stimulation by isoproterenoi s independent of' the 
receptor phosphorylation, Most tikely, this morons© 
results from the phosphorylation of  other components 
of the signalling pathway [16-18], which in turn leads to 
the increase in basal and forskolin.stimulated activities, 
In this respect, it is noteworthy that PMA induces very 
similar increases in basal and stimulated adenylyl 
cyclas¢ activities (basal: 2.4.fold, isoproterenol- 
stimulated: 2.9.reid, t'orskolin-stimulated: 1,9-fold; 
Table I). 
The hypothesis that PKC phosphorylation of  the 
receptor decreases its coupling to G, while the 
phosphorylation of distinct components of the adenylyl 
cyclase pathway increases the reactivity of the enzyme 
itself is supported by several observations. Patya et al, 
[3"/] reported that PMA treatment of  murme 
thymocytes reduced the isoproterenoI stimulated cAM P 
accumulation while potentiating the cAMP production 
induced by cholera toxin, More recently, Johnson et al, 
[39] reported that PMA treatment of  1321N1 human 
astrocytoma ceils induced a desensitization of  the /3. 
adrenergic-stimulated a enylyl cyclase activity in a 
membrane preparation whereas a marked increase o f  
the forskolin-stimulated adenylyl cyclase activity was 
observed in intact cells, 
The results presented here suggest hat PMA treat- 
ment modulates the ~3.adrenergic-stimulated adenylyl 
cyclase activity by affecting distinct components of the 
signalling pathway. The PMA treatment increases the 
eff icacy of  both forskolin and isoproterenol to 
stimulate the adenylyl cyclase, most likely via the PKC- 
mediated phosphorylation of  the adenylyl cyclase 
and/or  Gi [16-18]. In contrast, the phosphorylation of
the /3zAR by PKC results in a reduced ability of the 
receptor to couple to Gs, 
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